The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Targeting p53 in MDS
David Sallman
• 2 Sep 2020
David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses p53 mutations in the context of patients with myelodysplastic syndromes (MDS) and it’s association with survival. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
